MyMD Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
QCLS$0.37+8.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
December 31, 2023 and 2022
| As of | ||
|---|---|---|
| December 31, 2023 | December 31, 2022 | |
| ASSETS | ||
| Current Assets | ||
| Cash and Cash Equivalents | $2,681,010 | $749,090 |
| Marketable Securities | 2,242,106 | 4,086,902 |
| Prepaid Expenses | 893,226 | 565,787 |
| Total Current Assets | 5,816,342 | 5,401,779 |
| Non-Current Assets | ||
| Operating Lease Right-of-Use Assets | 47,389 | 139,662 |
| Goodwill | 10,498,539 | 10,498,539 |
| Investment in Oravax, Inc. | 1,500,000 | 1,500,000 |
| Total Non-Current Assets | 12,045,928 | 12,138,201 |
| Total Assets | $17,862,270 | $17,539,980 |
| LIABILITIES | ||
| Current Liabilities | ||
| Trade and Other Payables | $3,716,218 | $2,673,221 |
| Due to MyMD Florida Shareholders | 29,982 | 29,982 |
| Operating Lease Liability | 48,870 | 65,780 |
| Derivative Liabilities | 61,000 | - |
| Warrant Liabilities | 867,000 | - |
| Dividends Payable | 265,019 | - |
| Total Current Liabilities | 4,988,089 | 2,768,983 |
| Non-Current Liabilities | ||
| Deferred Compensation Payable | 100,538 | - |
| Operating Lease Liability, net of current portion | - | 75,941 |
| Total Non-Current Liabilities | 100,538 | 75,941 |
| Total Liabilities | $5,088,627 | $2,844,924 |
| Commitments and Contingencies | - | - |
| Series F Convertible Preferred Stock, with par value $0.001 per share and a stated value of $1,000 per share, 15,000 and 0 shares designated as of December 31, 2023 and December 31, 2022, 6,833 and 0 shares issued and outstanding as of December 31, 2023 and December 31, 2022. Liquidation preference of $6,833,500 plus dividends at 10% per annum of $265,350 as of December 31, 2023. | 404,071 | - |
| STOCKHOLDERS’ EQUITY | ||
| Preferred Stock, with par value $0.001 per share, 50,000,000 total preferred shares authorized | ||
| Series D Convertible Preferred Stock, 211,353 shares designated, with par value $0.001 per share and a stated value of $0.01 per share, 72,992 shares issued and outstanding as of December 31, 2023 and December 31, 2022 | 144,524 | 144,524 |
| Common stock, par value $0.001 per share, 16,666,666 shares authorized 2,018,857 and 1,315,674 issued and outstanding as of December 31, 2023 and December 31, 2022 | 2,019 | 1,316 |
| Additional Paid In Capital | 114,200,096 | 108,308,120 |
| Accumulated Deficit | (101,977,067) | (93,758,904) |
| Total Stockholders’ Equity | 12,369,572 | 14,695,056 |
| Total Liabilities and Stockholders’ Equity | $17,862,270 | $17,539,980 |
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.